Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. DFTX
8. LLY
9. RGNX
10. LCO

Go back to Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 813,071       

ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 813,071       

ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 813,071